Long-term follow-up of therapy with intermittent etidronate disodium in paget's disease of bone☆
References (30)
- et al.
Diphosphonates and Paget's disease of bone
Lancet
(1971) - et al.
Clinical and biochemical effects of EHDP in Paget's disease of bone: patterns of response to initial treatment and to long-term therapy
Metab Bone Dis Relat Res
(1981) - et al.
Diphosphonates in Paget's disease
Lancet
(1974) - et al.
Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease
Lancet
(1984) Experimental basis for the clinical use of diphosphonates in Paget's disease of bone
Arthritis Rheum
(1980)- et al.
Treatment of Paget's disease of bone with ethane-1, hydroxy-1, 1 diphosphonate (EHDP) at a low dosage (5 mg/kg/day)
Clin Orthop
(1983) - et al.
Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans)
N Engl J Med
(1973) - et al.
Disodium etidronate in the treatment of Paget's disease of bone (osteitis deformans): results of a one year study
JAMA
(1974) - et al.
Sodium etidronate in the treatment of Paget's disease of bone: a study of long term results
Ann Intern Med
(1977) - et al.
Changes in renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man
Clin Sci Mol Med
(1975)
Radiological assessment of osteoarthrosis
Ann Rheum Dis
(1957)
BMDP statistical software
(1983)
Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP)
Clin Orthop
(1983)
Paget's disease of bone
Cited by (62)
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone
2004, BoneCitation Excerpt :The mechanism by which resistance to bisphosphonates occurs in Paget’s disease is unknown, as is the mechanism by which the disease remains responsive to other drugs of the same class. The phenomenon was first noted with etidronate, which appeared more effective in patients as an initial course of treatment than on repeat administration [14]. When etidronate resistance developed, the disease remained responsive to other bisphosphonates such as tiludronate, pamidronate, or risedronate [7,15–17].
Monitoring treated Paget's disease and indications for retreatment
2003, Revue du Rhumatisme (Edition Francaise)Bisphosphonates for Paget's disease of bone in adults
2017, Cochrane Database of Systematic Reviews
- ☆
This work was supported in part by grants from the General Clinical Research Center (5MO 1RR-261-08) of the National Institutes of Health, the Elks Paget's Disease Research Fund 948, and the Proctor and Gamble Company.
Copyright © 1985 Published by Excerpta Medica Inc.